Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Bonus News from MarketBeat Is Abbott's January Pullback a Good Time to Buy? Written by Thomas Hughes. Article Published: 1/24/2026. 
Quick Look - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback has made the stock look attractively valued. The drop—driven more by market angst than by any clear weakness in the business—appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia's money and showed the world that assets can be seized. Now major nations want out. There's only one asset no one can freeze: gold. Get the name and ticker of one stock positioned for this shift. The zone in question lines up with the 2022–2024 trading range, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating shares. Abbott Laboratories Growth Accelerates Some metrics in Abbott Laboratories' Q4 results and guidance missed expectations, but revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth lagged by several hundred basis points, yet margin strength helped offset that shortfall: adjusted earnings per share rose about 12%, finishing slightly above consensus. By segment, Abbott's diversified healthcare portfolio showed resilience. Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those declines. The pharmaceuticals segment rose about 9%, aided by generics and strength in emerging markets, while Med Tech grew roughly 12.3%, with broad-based gains across subsegments. Margins also improved. A favorable product mix, strength in Med Tech, lower COVID-related sales and operational efficiencies all contributed. While some analysts had expected even stronger margin expansion, the improvements support the company's outlook. Looking ahead, Abbott expects earnings to grow roughly 10% in 2026, outpacing revenue growth and supporting its capital return program. Capital returns are central to the buying case. Abbott is a Dividend King, with more than 50 consecutive years of payout increases, and it retains capacity to continue that trend. After the pullback the stock yields about 2.5%, and Abbott pays out less than half of expected earnings, leaving room to fund share buybacks—another important tool that helps offset dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price-target cuts the morning of the earnings release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while investing in growth, and the medium-term growth outlook remains meaningful. The consensus share price target reported by MarketBeat implies upside of as much as 30%, which could push the stock toward new highs; even the low-end targets project some upside. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and strategic acquisitions. The acquisition of Exact Sciences, for example, would broaden Abbott's revenue and profit mix and enhance its product pipeline. The recent sell-off has been sharp and could still deepen. That said, institutions accumulated shares through 2025 and are likely buyers at these discounted levels. There is tentative support in the $105–$110 area, though it is not yet confirmed. Shares could drift lower to the bottom of the buy zone—potentially toward $95 or below—before a sustained rebound.
| 
